Study on glutathionesulphonic acid as biodistribution promoter: Concomitant use effect on verapamil hydrochloride and tegafur

Y. Ohkawa, K. Higashiyama, S. Sugaya, T. Asoh, H. Maeda, Kenji Sasaki, T. Nakayama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effect of glutathionesulphonic acid (N-(N-γ-L-glutamyl-L-β-sulphoalanylglycine, GSO3H), which is one of the minor metabolites of glutathione (GSH), on the pharmacokinetics of verapamil hydrochloride (verapamil·HCI) and tegafur was investigated in rats. GSO3H was concomitantly used as sodium salt (GSO3Na). No significant change by the concomitant use of GSO3Na was recognized in the pharmacokinetics parameters of verapamil·HCI and tegafur, and plasma elimination of both substances was not affected by GSO3Na. The tissue-to-plasma concentration ratio (Kp) of verapamil·HCI in the lung 5 min after its administration under concomitant use of GSO3Na rose significantly, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs. On the other hand, a significant difference of Kp of tegafur under a steady state concentration of GSO3Na was not recognized in any organs. It seemed that the elevation of a lipid solubility (oil water partition coefficient) of verapamil·HCI by the concomitant use of GSO3Na was related to the increase of the Kp value of verapamil·HCI in the lung. The partition coefficient of GSO3Na itself decreased when it was used concomitantly with verapamil·HCI.

Original languageEnglish
Pages (from-to)378-384
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Volume24
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Tegafur
Verapamil
Acids
Pharmacokinetics
Lung
glutathionesulfonic acid sodium salt
Solubility
Glutathione
Oils
Salts
Sodium
Lipids
Water

Keywords

  • Biodistribution promoter
  • Concomitant use
  • Drug/metabolite interaction
  • Glutathionesulphonic acid
  • Tegafur
  • Verapamil hydrochloride

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Study on glutathionesulphonic acid as biodistribution promoter : Concomitant use effect on verapamil hydrochloride and tegafur. / Ohkawa, Y.; Higashiyama, K.; Sugaya, S.; Asoh, T.; Maeda, H.; Sasaki, Kenji; Nakayama, T.

In: Biological and Pharmaceutical Bulletin, Vol. 24, No. 4, 2001, p. 378-384.

Research output: Contribution to journalArticle

Ohkawa, Y. ; Higashiyama, K. ; Sugaya, S. ; Asoh, T. ; Maeda, H. ; Sasaki, Kenji ; Nakayama, T. / Study on glutathionesulphonic acid as biodistribution promoter : Concomitant use effect on verapamil hydrochloride and tegafur. In: Biological and Pharmaceutical Bulletin. 2001 ; Vol. 24, No. 4. pp. 378-384.
@article{2a654c6d88ec4ba58dfdfa861f9bce82,
title = "Study on glutathionesulphonic acid as biodistribution promoter: Concomitant use effect on verapamil hydrochloride and tegafur",
abstract = "The effect of glutathionesulphonic acid (N-(N-γ-L-glutamyl-L-β-sulphoalanylglycine, GSO3H), which is one of the minor metabolites of glutathione (GSH), on the pharmacokinetics of verapamil hydrochloride (verapamil·HCI) and tegafur was investigated in rats. GSO3H was concomitantly used as sodium salt (GSO3Na). No significant change by the concomitant use of GSO3Na was recognized in the pharmacokinetics parameters of verapamil·HCI and tegafur, and plasma elimination of both substances was not affected by GSO3Na. The tissue-to-plasma concentration ratio (Kp) of verapamil·HCI in the lung 5 min after its administration under concomitant use of GSO3Na rose significantly, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs. On the other hand, a significant difference of Kp of tegafur under a steady state concentration of GSO3Na was not recognized in any organs. It seemed that the elevation of a lipid solubility (oil water partition coefficient) of verapamil·HCI by the concomitant use of GSO3Na was related to the increase of the Kp value of verapamil·HCI in the lung. The partition coefficient of GSO3Na itself decreased when it was used concomitantly with verapamil·HCI.",
keywords = "Biodistribution promoter, Concomitant use, Drug/metabolite interaction, Glutathionesulphonic acid, Tegafur, Verapamil hydrochloride",
author = "Y. Ohkawa and K. Higashiyama and S. Sugaya and T. Asoh and H. Maeda and Kenji Sasaki and T. Nakayama",
year = "2001",
doi = "10.1248/bpb.24.378",
language = "English",
volume = "24",
pages = "378--384",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Study on glutathionesulphonic acid as biodistribution promoter

T2 - Concomitant use effect on verapamil hydrochloride and tegafur

AU - Ohkawa, Y.

AU - Higashiyama, K.

AU - Sugaya, S.

AU - Asoh, T.

AU - Maeda, H.

AU - Sasaki, Kenji

AU - Nakayama, T.

PY - 2001

Y1 - 2001

N2 - The effect of glutathionesulphonic acid (N-(N-γ-L-glutamyl-L-β-sulphoalanylglycine, GSO3H), which is one of the minor metabolites of glutathione (GSH), on the pharmacokinetics of verapamil hydrochloride (verapamil·HCI) and tegafur was investigated in rats. GSO3H was concomitantly used as sodium salt (GSO3Na). No significant change by the concomitant use of GSO3Na was recognized in the pharmacokinetics parameters of verapamil·HCI and tegafur, and plasma elimination of both substances was not affected by GSO3Na. The tissue-to-plasma concentration ratio (Kp) of verapamil·HCI in the lung 5 min after its administration under concomitant use of GSO3Na rose significantly, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs. On the other hand, a significant difference of Kp of tegafur under a steady state concentration of GSO3Na was not recognized in any organs. It seemed that the elevation of a lipid solubility (oil water partition coefficient) of verapamil·HCI by the concomitant use of GSO3Na was related to the increase of the Kp value of verapamil·HCI in the lung. The partition coefficient of GSO3Na itself decreased when it was used concomitantly with verapamil·HCI.

AB - The effect of glutathionesulphonic acid (N-(N-γ-L-glutamyl-L-β-sulphoalanylglycine, GSO3H), which is one of the minor metabolites of glutathione (GSH), on the pharmacokinetics of verapamil hydrochloride (verapamil·HCI) and tegafur was investigated in rats. GSO3H was concomitantly used as sodium salt (GSO3Na). No significant change by the concomitant use of GSO3Na was recognized in the pharmacokinetics parameters of verapamil·HCI and tegafur, and plasma elimination of both substances was not affected by GSO3Na. The tissue-to-plasma concentration ratio (Kp) of verapamil·HCI in the lung 5 min after its administration under concomitant use of GSO3Na rose significantly, however, this effect disappeared 120 min after administration. No significant change was recognized in other organs. On the other hand, a significant difference of Kp of tegafur under a steady state concentration of GSO3Na was not recognized in any organs. It seemed that the elevation of a lipid solubility (oil water partition coefficient) of verapamil·HCI by the concomitant use of GSO3Na was related to the increase of the Kp value of verapamil·HCI in the lung. The partition coefficient of GSO3Na itself decreased when it was used concomitantly with verapamil·HCI.

KW - Biodistribution promoter

KW - Concomitant use

KW - Drug/metabolite interaction

KW - Glutathionesulphonic acid

KW - Tegafur

KW - Verapamil hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=0035037718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035037718&partnerID=8YFLogxK

U2 - 10.1248/bpb.24.378

DO - 10.1248/bpb.24.378

M3 - Article

C2 - 11305599

AN - SCOPUS:0035037718

VL - 24

SP - 378

EP - 384

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -